This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.

George M. Simpson, MD; Ramy A. Mahmoud, MD; Robert A. Lasser, MD; Mary Kujawa, MD; Cynthia A. Bossie, PhD; Ibrahim Turkoz, MS; Steven Rodriguez, MS; and Georges M. Gharabawi, MD

Published: August 15, 2006

Article Abstract

Objective: This study examined the effects of 2doses of long-acting risperidone injection in patients withschizophrenia or schizoaffective disorder.

Method: This 52-week, prospective, randomized,double-blind, multicenter, international study includedclinically stable outpatients with schizophrenia orschizoaffective disorder (DSM-IV criteria). Settings includedphysicians’ offices and clinics. Patients received a fixed doseof long-acting risperidone (25 or 50 mg) every 2 weeks. Primaryoutcome was time to relapse, defined as either rehospitalizationor other exacerbation criteria. Other assessments included thePositive and Negative Syndrome Scale, Clinical GlobalImpressions-Severity of Illness scale, and functional andquality-of-life measures. Safety was assessed viatreatment-emergent adverse events, laboratory tests, and movementdisorder rating scales. Data were collected from December 2002 toSeptember 2004.

Results: A total of 324 patients were randomizedto 25 mg (N = 163) or 50 mg (N = 161) of long-acting risperidone.Time to relapse was comparable (p = .131) for both groups.Projected median time to relapse was 161.8 weeks (95% CI = 103.0 to254.2) with 25 mg and 259.0 weeks (95% CI = 153.6 to 436.8) with 50mg. One-year incidences of relapse were 21.6% (N = 35) and 14.9%(N = 24), respectively (p = .059). Psychiatric hospitalization wasthe reason for relapse for 16 (10%) in the 25-mg group and 10(6%) in the 50-mg group. Patients experienced statisticallysignificant but modest improvements at endpoint in most measures(i.e., psychotic symptoms, functioning, movement disorderseverity) with both doses, with no significant between-groupdifferences.

Conclusion: In this 1-year study, long-actingrisperidone was associated with low relapse and rehospitalizationrates, indicating that doses of 25 to 50 mg are appropriate forlong-term treatment in schizophrenia.

Clinical Trials Registration: ClinicalTrials.govidentifier NCT00297388.

Volume: 67

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF